Anti-Mad2L1 antibody
4
(1 Review)
|
(12 Publications)
Rabbit Polyclonal Mad2L1 antibody. Suitable for IP, WB, IHC-P, ICC/IF and reacts with Human, Rat samples. Cited in 12 publications. Immunogen corresponding to Synthetic Peptide within Human MAD2L1 aa 150 to C-terminus.
View Alternative Names
MAD2, MAD2L1, Mitotic spindle assembly checkpoint protein MAD2A, HsMAD2, Mitotic arrest deficient 2-like protein 1, MAD2-like protein 1
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)
Immunohistochemical analysis of paraffin-embedded human a549 xenograft tissue stained for MAD2L1 protein at cytoplasm and nucleus with ab97777 at a 1/250 dilution.
Antigen retrieval : EDTA based buffer, (pH 8.0), 15min
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-Mad2L1 antibody (AB97777)
Immunofluorescence analysis of Mad2L1 in Human osteosarcoma cell line U2OS, using ab97777 at 1/1000 dilution.
1 : Mad2L1
2 : ACA
3 : merged with DAPI
Cells were fixed with 4% PFA/PBS for 15min, RT and blocked with 2.5% BSA/PBS.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)
Immunohistochemical analysis of Mad2L1 in paraffin embedded DLD-1 xenograft, using ab97777 at a 1/500 dilution.
- IP
Supplier Data
Immunoprecipitation - Anti-Mad2L1 antibody (AB97777)
Immunoprecipitation of MAD2L1 protein from 293T whole cell extracts using 5 µg of ab97777. Western blot analysis was performed using ab97777.
All lanes:
Immunoprecipitation - Anti-Mad2L1 antibody (ab97777) at 5 µg
Lane 1:
293T whole cell extracts (Input)
Lane 2:
293T whole cell extracts with control IgG (-)
Lane 3:
293T whole cell extracts (+)
Secondary
All lanes:
Anti-Rabbit IgG
Predicted band size: 24 kDa
false
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)
Immunohistochemical analysis of paraffin-embedded rat fore brain tissue stained for MAD2L1 protein at nucleus with ab97777 at a 1/500 dilution.
Antigen retrieval : EDTA based buffer, (pH 8.0), 15min
- WB
Supplier Data
Western blot - Anti-Mad2L1 antibody (AB97777)
Samples were separated by 12% SDS-PAGE.
All lanes:
Western blot - Anti-Mad2L1 antibody (ab97777) at 1/1000 dilution
Lane 1:
293T whole cell extracts at 30 µg
Lane 2:
MAD2L1 shRNA transfected 293T whole cell extracts at 30 µg
Secondary
All lanes:
HRP-conjugated anti-rabbit IgG antibody
Predicted band size: 24 kDa
false
- WB
Supplier Data
Western blot - Anti-Mad2L1 antibody (AB97777)
Samples were separated by 12% SDS-PAGE.
All lanes:
Western blot - Anti-Mad2L1 antibody (ab97777) at 1/1000 dilution
Lane 1:
Jurkat whole cell extracts at 30 µg
Lane 2:
Raji whole cell extracts at 30 µg
Lane 3:
NCI-H929 whole cell extracts at 30 µg
Secondary
All lanes:
HRP-conjugated anti-rabbit IgG antibody
Predicted band size: 24 kDa
false
- WB
Unknown
Western blot - Anti-Mad2L1 antibody (AB97777)
All lanes:
Western blot - Anti-Mad2L1 antibody (ab97777) at 1/1000 dilution
Lane 1:
HepG2 whole cell lysate at 30 µg
Lane 2:
MOLT4 whole cell lysate at 30 µg
Lane 3:
Raji whole cell lysate at 30 µg
Predicted band size: 24 kDa
false
- WB
CiteAb
Western blot - Anti-Mad2L1 antibody (AB97777)
Western Blotting using Anti-Mad2L1 antibodyAnti-Mad2L1 antibody, ab97777. Publication image from Chen, J. et al., 2016, Nat Commun, 26743940. Legend direct from paper.
Cep57 contributes to activation of the spindle assembly checkpoint.(a,b) HeLa cells with 100 nM nocodazole treatment after co-transfection with H2B-RFP and negative control (NC)-, Cep57-, Mad1- or Mad2-siRNA for 48 h. (a) Time-lapse images of HeLa cells. The numbers indicate the time (minutes) after entry into mitosis. Arrowhead, multiple nuclei. Scale bar, 5 µm. (b) Quantification of mitotic duration of HeLa cells from a. Scatter plots show data from three independent experiments. (c) Quantification of mitotic duration of live HeLa cells with 80 nM taxol treatment after co-transfection with H2B-RFP and negative control (NC)-, Cep57-, Mad1- or Mad2-siRNA for 48 h. Scatter plots show data from three independent experiments. (d) Diagram of experimental design. The siRNA-transfected HeLa cells were synchronized by double-thymidine block, and released into nocodazole. (e–g) HeLa cells were treated as in d. (e) After 12 h nocodazole treatment, mitotic cell lysates were used to perform immunoprecipitation (IP) and western blotting assays with the indicated antibodies. WCL, whole-cell lysate. (f) Western blots of the indicated proteins in HeLa cells after the indicated nocodazole (Noc.) treatment time. (g) Quantification of the protein levels of securin and cyclin B1 from (f). The experiment was repeated three times. For b,c and g, data are mean±s.e.m. ****P<0.0001; ***P<0.001; **P<0.01; *P<0.05; NS, not significant (unpaired two-tailed Student's t-test). DIC, differential interference contrast.
false
- WB
CiteAb
Western blot - Anti-Mad2L1 antibody (AB97777)
Western Blotting using Anti-Mad2L1 antibodyAnti-Mad2L1 antibody, ab97777. Publication image from Chen, J. et al., 2016, Nat Commun, 26743940. Legend direct from paper.
Cep57 contributes to activation of the spindle assembly checkpoint.(a,b) HeLa cells with 100 nM nocodazole treatment after co-transfection with H2B-RFP and negative control (NC)-, Cep57-, Mad1- or Mad2-siRNA for 48 h. (a) Time-lapse images of HeLa cells. The numbers indicate the time (minutes) after entry into mitosis. Arrowhead, multiple nuclei. Scale bar, 5 µm. (b) Quantification of mitotic duration of HeLa cells from a. Scatter plots show data from three independent experiments. (c) Quantification of mitotic duration of live HeLa cells with 80 nM taxol treatment after co-transfection with H2B-RFP and negative control (NC)-, Cep57-, Mad1- or Mad2-siRNA for 48 h. Scatter plots show data from three independent experiments. (d) Diagram of experimental design. The siRNA-transfected HeLa cells were synchronized by double-thymidine block, and released into nocodazole. (e–g) HeLa cells were treated as in d. (e) After 12 h nocodazole treatment, mitotic cell lysates were used to perform immunoprecipitation (IP) and western blotting assays with the indicated antibodies. WCL, whole-cell lysate. (f) Western blots of the indicated proteins in HeLa cells after the indicated nocodazole (Noc.) treatment time. (g) Quantification of the protein levels of securin and cyclin B1 from (f). The experiment was repeated three times. For b,c and g, data are mean±s.e.m. ****P<0.0001; ***P<0.001; **P<0.01; *P<0.05; NS, not significant (unpaired two-tailed Student's t-test). DIC, differential interference contrast.
false
Reactivity data
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Mad2L1 serves as an essential component of the mitotic checkpoint complex. It forms a complex with other proteins such as Mad1 BubR1 and Cdc20 inhibiting the anaphase-promoting complex/cyclosome (APC/C). This interaction prevents the premature separation of sister chromatids by blocking the degradation of securin and cyclin B. These actions ensure that cells do not progress to anaphase until all chromosomes are correctly attached to the mitotic spindle.
Pathways
Mad2L1 interacts with proteins that regulate the spindle assembly checkpoint pathway and the cell cycle. It holds particular prominence within the mitotic spindle assembly checkpoint where it regulates progression from metaphase to anaphase through its interaction with proteins like Cdc20 and BubR1. Mad2L1 also plays a role in the DNA damage response cycle highlighting its importance in maintaining genomic stability.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (12)
Recent publications for all applications. Explore the full list and refine your search
Chemical biology & drug design 104:e70012 PubMed39487106
2024
Applications
Unspecified application
Species
Unspecified reactive species
The EMBO journal 42:e111587 PubMed37063065
2023
Applications
Unspecified application
Species
Unspecified reactive species
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 9:e2104291 PubMed36031387
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of breast cancer 25:178-192 PubMed35775700
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell biology international 46:840-848 PubMed35143103
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cancer cell international 21:634 PubMed34838000
2021
Applications
Unspecified application
Species
Unspecified reactive species
Biochimica et biophysica acta. Molecular cell research 1868:118929 PubMed33310066
2020
Applications
Unspecified application
Species
Unspecified reactive species
Computational and mathematical methods in medicine 2020:2953598 PubMed33204298
2020
Applications
Unspecified application
Species
Unspecified reactive species
Oncogenesis 9:43 PubMed32366853
2020
Applications
Unspecified application
Species
Unspecified reactive species
Cell reports 23:852-865 PubMed29669289
2018
Applications
Unspecified application
Species
Human
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com